Transcriptomic analysis of Ovarian Cancer Progression and Treatment (combination of Pembrolizumab with Bevacizumab and Metronomic Cyclophosphamide) Response: Identifying DEGs and Pathways Across the Three Time Points.

The three drugs have shown to enhance the immune response against cancer cells giving pembrolizumab, bevacizumab, and cyclophosphamide together work better in treating patients with recurrent ovarian cancer. The patient were divided into three groups and their samples were treated across the three time points i.e. baseline(BLBX), after four cycles of treatment(C4BX) and the end of treatment(EOTBX). The data was analyzed using various techniques such as machine learning, clustering, and pathway analysis to identify biomarkers that are associated with treatment response. Network and Pathway analysis was also performed to determine the significance of the results obtained.